INmune Bio announced progress toward UK regulatory approval for Ebstrocel, a treatment for recessive dystrophic epidermolysis bullosa (RDEB), with a complete Marketing Authorization Application planned for early February 2027 and potential approval by mid-2027. The company also advanced preparations for a U.S. Biologics License Application targeting mid-2027 submission and established international patient access agreements. Financially, INmune Bio reported a Q3 2026 net loss of approximately $4.7 million, improved from $6.5 million in Q3 2025, with cash reserves of $16.3 million and recent capital raises supporting operations into late 2027. The company is focused on regulatory milestones, manufacturing readiness, and expanding patient access to maximize value for shareholders and patients.
INmune Bio's Q3 2026 results and business update come amid a challenging Health sector on Pluang, where only 16 of 150 US stocks rose as of Nov 06, 2026 04:11 WIB. For readers following Health stocks, here is Pluang's market snapshot: FLNA (Cassava Sciences Inc) dropped 21.02% to USD 0.46 with a typical hold time of 39 days and 79% buy orders; XRAY (DENTSPLY SIRONA Inc) fell 17.18% to USD 8.82 with a 74-day hold time; TXG (10X Genomics Inc) declined 15.60% to USD 56.99 with an 88% sell order activity and 92-day hold time.
Grupo Aeroportuario del Sureste (ASUR) reported a 0.9% decrease in total passenger traffic for October 2026 compared to the previous year, totaling 9.3 million passengers. While Colombia, Puerto Rico, Brazil, and Ecuador saw modest increases in domes...
BioAge Labs initiated dosing in its Phase 2 trial (QUELL-DME) for BGE-102, an oral NLRP3 inhibitor aimed at treating diabetic macular edema, with topline results expected in late 2027. The company also completed enrollment in a Phase 2 cardiovascular...
Vaalco Energy announced a quarterly cash dividend of $0.0625 per share for Q4 2026, payable on December 22, 2026, to shareholders of record as of November 20, 2026. This marks the company's 20th consecutive quarterly dividend, reflecting its strong c...
Mercer International reported a significant improvement in its third quarter 2026 Operating EBITDA, narrowing losses to negative $2.9 million from negative $28.1 million a year earlier, driven by cost savings and government grants. The company has en...
Ameren Corporation reported third quarter 2026 GAAP diluted EPS of $2.42, up from $2.35 in 2025, driven by infrastructure investments and higher electric sales. The company raised its 2026 earnings guidance to $5.35-$5.55 per share and set 2027 guida...
